Skip to content
    SOLV
    Earnings call· Mar 2026(Q1 FY26)

    Solventum Q1 FY26 earnings call SOLV

    May 5, 2026 Source

    Executive summary

    Solventum Q1 FY26 — Strong Start, Ahead of Plan, Accelerated Buybacks

    Solventum delivered a strong first quarter, exceeding sales and earnings expectations, driven by solid commercial execution, new product launches, and operational efficiencies. The company is making significant progress on its separation from 3M and portfolio optimization, including accelerating share repurchases. Management expressed confidence in achieving full-year guidance and long-range plan targets, despite navigating ongoing separation efforts and macro headwinds.

    Highlights

    5

    • Organic sales growth of 2.1% exceeded plan and expectations.

    • Adjusted EPS of $1.48 grew 11% year-over-year, ahead of expectations.

    • Gross margins improved 80 basis points year-over-year to 56.4%.

    • Acera acquisition contributed $28 million to reported sales in Advanced Wound Care.

    • Repurchased 923,000 shares for $67 million in Q1 FY26.

    Concerns

    2

    • Annual tariff headwinds are expected to be $100 million to $120 million.

    • A sales timing benefit of over $100 million is expected in Q2 due to ERP cutover, which will reverse in Q3.

    Guidance & targets

    9
    CategoryTargetConfidence
    Full-year organic sales growth
    Maintained
    high materiality
    High
    Full-year free cash flow
    Maintained
    high materiality
    High
    Full-year adjusted EPS
    Toward the high end of $6.40 to $6.60 range
    high materiality
    High
    Full-year operating margin
    21% to 21.5%
    high materiality
    High
    Full-year effective tax rate
    19.5% to 20.5%
    medium materiality
    High
    Annual tariff headwinds
    $100 million to $120 million
    high materiality
    High
    Operating margin expansion
    50 to 100 basis points
    high materiality
    High
    ERP cutover sales timing benefit
    Over $100 million
    medium materiality
    High
    Long-range plan organic sales growth
    4% to 5%
    high materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    MedSurg
    Strong underlying performance in growth driver areas, including Negative Pressure Wound Therapy. Acera acquisition opens doors to fast-growth acute care synthetic tissue space. Infection Prevention and Surgical Solutions performed well despite a tough prior-year comparison.
    Advanced Wound Care organic growth: 2.1%Acera contribution to reported sales: $28 millionInfection Prevention and Surgical Solutions organic growth: 0.6%
    		$1.2 billion1.2%——
    Dental Solutions
    Growth driven by innovation and separation-related timing benefits. Core restoratives led performance, leveraging new product launches and improved back orders.
    		$354 million3.4%——
    Health Information Systems
    Strong results driven by Revenue Cycle Management and Performance Management solutions. Autonomous coding continues to gain traction, with international expansion providing a tailwind. Clinician Productivity Solutions experienced expected declines.
    Clinician Productivity Solutions decline: double-digit
    		$342 million4.7%——

    Operational metrics

    22
    Organic sales growth
    2.1%vs prior year
    Q1 FY26

    Reported organic sales growth for the quarter.

    Reported sales growth
    -3%vs prior year
    Q1 FY26

    Reported sales growth for the quarter, impacted by acquisitions and divestitures.

    Foreign currency benefit to reported growth
    270
    Q1 FY26

    Foreign currency provided a benefit to reported sales growth.

    Net impact of acquisitions and divestitures headwind
    780
    Q1 FY26

    Net impact of portfolio changes created a headwind on reported sales growth.

    SKU rationalization impact on sales
    100
    Q1 FY26

    Impact of SKU rationalization on Q1 sales, tracking in line with full-year expectation.

    Organic growth normalized
    ~4%
    Q1 FY26

    Normalized organic growth after adjusting for separation-related timing benefits and Acera contribution.

    Separation-related timing benefits (Q1 sales)
    70
    Q1 FY26

    Sales volume accelerated from Q2 into Q1 due to separation-related timing.

    Gross margin
    56.4%improved 80 bps over prior year
    Q1 FY26

    Gross margin performance for the quarter, exceeding expectations.

    Operating margin
    19.5%similar to last year
    Q1 FY26

    Adjusted operating margin for the quarter.

    Effective tax rate
    20.4%
    Q1 FY26

    Effective tax rate for the quarter, within full-year guidance range.

    Cash and equivalents
    $561 million
    Q1 FY26

    Cash and equivalents balance at the end of the quarter.

    Net debt
    $4.5 billion
    Q1 FY26

    Net debt balance at the end of the quarter.

    Share repurchases
    $67 million
    Q1 FY26

    Amount and number of shares repurchased in the first quarter.

    Share buyback authorization
    Up to $1 billion
    Ongoing

    Board approval for share buybacks.

    Transform for the Future savings program
    $500 million
    Multiyear

    Multiyear savings program to reshape operating structure and invest for the long term.

    TSA exits
    >50%
    Q1 FY26

    Percentage of transition service agreements exited.

    System applications migrated
    75%
    Q1 FY26

    Percentage of system applications migrated, including ERP cutover in Asia Pacific.

    Distribution centers
    54down from prior
    Q1 FY26

    Number of distribution centers worldwide after streamlining efforts.

    New product launches
    Close to 20
    Next 2 years

    Expected number of new product launches, with a meaningful portion in growth driver areas.

    Autonomous coding customer adoption target
    Close to 50%
    Strat plan period

    Target for customers adopting autonomous coding during the strategic plan period.

    Autonomous coding potential
    80-90%
    Future

    Management's view on the percentage of all coding that can eventually be done fully autonomous.

    Operating expenses
    $740 millionlower in dollars, higher as % of sales vs prior year
    Q1 FY26

    Operating expenses for Q1, impacted by seasonality.

    Industry KPIs

    7
    MetricValueDetails
    Tariff impact$100 million to $120 millionUSD
    Pricing realized priceWithin expected range
    New product launch rampClose to 20 productscount
    Procedure volume growthPrimarily from volume
    FCF conversion leverage guidanceMaintained
    Segment franchise organic growthMedSurg: 1.2%; Advanced Wound Care: 2.1%; Infection Prevention and Surgical Solutions: 0.6%; Dental Solutions: 3.4%; Health Information Systems: 4.7%%
    Sales force commercial capacity buildOver 1,000 repscount

    Product announcements

    5
    ProductTypeDetails
    Clarity brandlaunch
    Filtek Easy Matchlaunch
    Clinpro Clearlaunch
    Test sterilization productslaunch
    V.A.C Peel and Place Dressingexpansion

    Deals & partnerships

    2
    AceraAcquisition of a fast-growth business aligned to existing call points, specifically in the acute care synthetic tissue space.

    Early integration is playing out as expected, reinforcing ability to identify, close, and integrate attractive assets. Slots perfectly into Advanced Wound Care infrastructure.

    Purification and Filtration (P&F) businessDivestiture of the Purification and Filtration business.$4 billion

    Separation is progressing well, with the majority of transition service agreements to be completed in 2027. Described as one of the best multiples in the sector.

    Risks & headwinds

    4
    Annual tariff headwindsFY26

    $100 million to $120 million

    Mitigation: Active supply chain mitigation strategies; Transform for the Future program provides additional firepower to offset headwinds.

    Inflationary impactsFY26

    Unquantified

    Mitigation: Offset by programmatic savings and portfolio moves, contributing to operating margin expansion.

    ERP cutover sales timing reversalQ3 FY26

    Over $100 million sales benefit in Q2 expected to reverse in Q3

    Mitigation: Advanced ordering strategy with customers and distributors to mitigate challenges during the U.S. and Canada ERP cutover in Q3. High proportion of sales through distribution in the U.S. provides a strong contingency.

    Separation-related timing benefitsQ1 FY26

    70 basis points of sales volume accelerated from Q2 into Q1

    Mitigation: Managed through advanced orders to keep customers stocked during registration blackouts and other separation activities.

    What to watch in Q2 FY26

    5

    ERP cutover sales reversal

    Q3 FY26
    CurrentOver $100M sales benefit in Q2
    TargetQuantification of reversal in Q3

    Why it matters

    This will impact Q3 reported sales and requires careful adjustment for underlying growth analysis.

    We estimate over $100 million of sales timing benefit in Q2 that we expect will reverse in 2026, mostly in Q3.

    Q&A highlights

    6

    Clarification on the expected $100M sales benefit in Q2 due to ERP cutover, specifically which segments will be impacted and how to model it.

    The $100M+ sales benefit in Q2 is due to advanced orders from customers/distributors ahead of the Q3 U.S. and Canada ERP cutover, primarily impacting IP&SS and Dental. This is a mitigation strategy to ease the transition. The full-year guidance remains unchanged, as the Q2 benefit is expected to reverse in the second half, mostly Q3. Management advises against modeling the precise Q2 impact, promising an update with actuals.

    “So as we called out in the prepared remarks, as you said, Brett, we are estimating over $100 million additional sales in Q2 as we're working with our customers and distributors to advance orders before we begin our Q3 cutover of ERPs in the U.S. and Canada. This is going to mostly impact IPSS and Dental to your question.”

    asked by Brett Fishbin · answered by Wayde McMillan

    2 min read5 chapters

    Detailed Narrative

    01

    Operational Efficiency and Separation Progress

    Solventum is making significant strides in its separation from 3M, having exited over 50% of transition service agreements (TSAs) and on track to exit over 90% by the end of 2026. The company successfully migrated 75% of its 1,200+ system applications, including a recent ERP cutover in Asia Pacific. Further facility moves, manufacturing expansion in South Dakota, and distribution center streamlining (down to 54 worldwide) are enhancing supply chain flexibility and operational efficiency.

    02

    Portfolio Optimization and Capital Allocation

    The company views portfolio optimization as a perpetual lever for value creation, demonstrated by SKU rationalization (more than halfway complete), the divestiture of the P&F business, and the acquisition of Acera. Acera, a fast-growth business aligned with existing call points, contributed $28 million in Q1 sales. Solventum has Board approval for up to $1 billion in share buybacks and plans to accelerate execution, balancing it with tuck-in acquisitions in a 'target-rich environment'.

    03

    Commercial Momentum and Innovation Pipeline

    Solventum's underlying commercial momentum is strong, reinforced by a rebuilt commercial engine with clearer accountability and specialized sales teams. Innovation is fueling this momentum, with close to 20 new products expected to launch over the next two years, primarily in growth driver areas. These launches are designed as a steady cadence of 'singles, doubles, and triples' to reduce risk and provide consistent fuel for the commercial teams.

    04

    Health Information Systems and Autonomous Coding

    The Health Information Systems (HIS) segment continues to perform strongly, driven by Revenue Cycle Management (RCM) and Performance Management solutions. The autonomous coding offering is gaining traction in both outpatient and inpatient settings, leveraging Solventum's unique data sets, rules, and algorithms to train AI for accurate and compliant reimbursement coding. The company believes 80-90% of coding can eventually be autonomous, targeting 50% customer adoption during the strategic plan period due to compelling economics (productivity, FTE reduction, improved revenue capture).

    05

    Gross Margin Strength and Future Outlook

    Despite tariff and inflationary headwinds, Q1 gross margins improved 80 basis points year-over-year to 56.4%, exceeding expectations due to programmatic savings, favorable portfolio moves, sales leverage, and mix. While Q1 benefited from these factors, management expects gross margins to normalize slightly below 56% for the remainder of the year. The Transform for the Future program, a multiyear $500 million savings initiative, is designed to proactively reshape the operating structure and offset headwinds, contributing to the committed 50-100 basis point operating margin expansion in 2026.

    AI-generated summary of the company’s earnings call. Not investment advice.